For Immediate Release: SCICANN THERAPEUTICS, FSD PHARMA, AFFINITY BIO PARTNERS AND COMPASSIONATE CARE CERTIFICATION CENTERS
PRESS RELEASE – October 31, 2018 7:30 AM Eastern Standard Time
SCICANN THERAPEUTICS, FSD PHARMA, AFFINITY BIO PARTNERS AND COMPASSIONATE CARE CERTIFICATION CENTERS
“SciCann Therapeutics and FSD Pharma announce selection of Affinity Bio Partners as the Clinical Research Organization in connection with Compassionate Care Certification Centers to launch the first clinical research study for Irritable Bowel Syndrome (IBS) in Pittsburgh, PA.”
ONTARIO, Canada, SPRING CITY, Pennsylvania and PITTSBURGH, Pennsylvania. –(BUSINESS WIRE)— SciCann Therapeutics and FSD Pharma Inc. announce the selection of Affinity Bio Partners as the Clinical Research Organization in connection with Compassionate Care Certification Centers to launch the first clinical research study for Irritable Bowel Syndrome in Pittsburgh, PA.
Dr. Zohar Koren, Chief Executive Officer of SciCann Therapeutics, stated “Selecting a CRO is a very crucial and strategic decision as it relates to initiating patient enrollment into our clinical research study in IBS with our proprietary “Steady Stomach” CBD combination product. We are very excited to commence our first US based clinical research study with Affinity Bio Partners, Compassionate Certification Centers and Dr. Bryan Doner. Additionally, we will be using AI Health Outcomes, CannaBot™ (an Artificial Intelligence Bot) for the patients enrolled in this study.”
“We are very pleased to have been selected as the Clinical Research Organization for SciCann Therapeutics’ IBS clinical study. We are thrilled to work alongside Compassionate Care Certifications Centers and Dr. Bryan Doner helping the unmet medical needs of IBS patients in the CBD clinical research industry. It is very important for us to pioneer the clinical research in lieu of studies in the CBD industry to aid the validity of the cannabis plant as it relates to therapeutic areas that it might help. We are equally excited to utilize the CannaBot from AI Health Outcomes in this clinical study,” said Christina DiArcangelo Puller, CEO, Affinity Bio Partners.
About Affinity Bio Partners
Affinity Bio Partners is a Clinical Research Organization (CRO) that provides best in class services while maintaining a personal approach. There are many CROs in the market, but there is only one that will give our client’s organization the attention, services and results. For more information on the company or general inquiries, please email: email@example.com or visit us atwww.affinitybiopartners.com. Follow us on twitter at AffinityBioP, Facebook, LinkedIn and Instagram.
About SciCann Therapeutics
ScICann Therapeutics is a Canadian-Israeli specialty pharmaceutical company, dedicated to the development and commercialization of novel and disruptive pharmaceutical products that target and modulate the endocannabinoid system. SciCann Therapeutics is active in the fields of oncology, pain management, neurodegenerative diseases and inflammatory disorders, and develops a line of proprietary products for the treatment of life-threatening conditions that present a high level of unmet need.
SciCann has created a network of collaborations with leading academic centers and medical institutions in Israel to engage in cutting edge science and rigorous clinical studies to develop its products, while using the permissive regulatory climate in Israel for performing its R&D programs quickly and efficiently.
About FSD Pharma (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9)
FSD Pharma is focused on the development of the highest quality indoor grown, pharmaceutical grade cannabis and on the research and development of novel cannabinoid-based treatments for several central nervous system disorders, including chronic pain, fibromyalgia and irritable bowel syndrome. The Company’s phase one growth plan involves the development of 25,000 square feet of indoor grow space at its Ontario facility and an additional 220,000 square feet, which pending approval by Health Canada, is expected to be operational in the first quarter 2019.
FSD facilities sit on 72 acres of land with 40 acres primed for development and an expansion capability of up to 3,896,000 square feet.
FSD’s wholly-owned subsidiary, FV Pharma, is a licensed producer of cannabis having received its cultivation license under the Access to Cannabis for Medical Purposes Regulations (ACMPR) on October 13, 2017 and is now operating under the recently enacted Cannabis Act. FV Pharma vision is to transform its current headquarters in a Kraft plant in Cobourg, Ontario into the largest hydroponic indoor grow facility in the world. FV Pharma intends to cover all aspects of this exciting, new industry, including cultivation, legal, processing, manufacturing, extracts and research and development.
About Compassionate Care Certifications Centers
Compassionate Certification Centers™ is a Syndikos Investments, LLC portfolio brand based in Middleton, Delaware, that produces the World Medical Cannabis Conference & Expo. Compassionate Certification Centers™ implements the first of its kind membership program for all types of healthcare providers to access medical cannabis research and patients throughout the U.S. states, district and territories. Membership program benefits feature tools and resources needed to operate healthcare providers’ own certification centers including: potential patients based on geography, research, full-spectrum marketing, peer networking, legal documents and services, cannabis education and CME credits, cannabis product training, and much more.
Compassionate Certification Centers™ is based in Pittsburgh, for more information visit compassionatecertificationcenters.com or join the discussion at Facebook, Twitter, LinkedIn, Instagram and Google+.
Neither the Canadian Securities Exchange nor its regulation services provider accepts responsibility for the adequacy or accuracy of this release.
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Corporation’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the development of the Corporation’s indoor cannabis facility and its business goals and objectives. The forward-looking information contained in this press release is made as of the date hereof, and the Corporation is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking-information. The foregoing statements expressly qualify any forward-looking information contained herein.
ON BEHALF OF SCICANN THERAPEUTICS:
Dr. Zohar Koren, Chief Executive Officer
ON BEHALF OF FSD PHARMA:
Zeeshan Saeed, President and Founder
Telephone: (416) 854-8884